Get the Stockscreener App
0.9346
0.94%
0.0087
After Hours:
.95
0.0154
+1.65%
Tempest Therapeutics Inc stock is traded at $0.9346, with a volume of 125.85K.
It is up +0.94% in the last 24 hours and down -13.46% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
See More
Previous Close:
$0.9259
Open:
$0.9052
24h Volume:
125.85K
Relative Volume:
0.86
Market Cap:
$14.93M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.1505
EPS:
-6.2098
Net Cash Flow:
$-26.38M
1W Performance:
-1.87%
1M Performance:
-13.46%
6M Performance:
-36.42%
1Y Performance:
-75.91%
1-Day Range:
$0.905
$0.9784
1-Week Range:
$0.8695
$1.035
52-Week Range:
$0.8695
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.9346 | 14.80M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
TradingKey - TradingKey
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TPST|Tempest Therapeutics Inc|Price:0.940|Chg%:-0.000 - TradingKey
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks
Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com
Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et
TPST|Tempest Therapeutics Inc|Price:0.930| - TradingKey
Tempest Announces Development Collaboration with Senlang - GlobeNewswire
Tempest Therapeutics (TPST) plans vote on supermajority and written-consent changes - Stock Titan
William Drake Richey Net Worth (2026) - GuruFocus
Tempest advances next-generation in vivo CAR T pipeline - BioWorld News
Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com - Investing.com South Africa
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial - Quiver Quantitative
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, - GlobeNewswire
Tempest's planned CAR-T study targets myasthenia gravis and MS - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants - Stock Titan
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter - Stock Titan
Tempest Therapeutics (TPST) Edges Lower as Stock Hovers Near Key Support LevelValue Stock Ideas - dars.gov.et
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
TPST Q1 2026 Earnings: Deep EPS Miss as Clinical-Stage Biotech Reports $2.53 Loss Per ShareEarnings Growth Analysis - DonanımHaber
Tempest Therapeutics (TPST) Rallies Modestly as Stock Holds Above Key SupportMomentum ETF - dars.gov.et
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - GlobeNewswire
Tempest Therapeutics Registers 2.43 Million Shares for Resale - Moomoo
Form S-3 Tempest Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
TPST Forecast — Price Target — Prediction for 2027 - TradingView
TPST: Selling Stockholders Plan to Offer 2.43 Million Shares - GuruFocus
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants - Stock Titan
3OS0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBITDA forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST) - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBIT forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Form 4 Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock By Investing.com - Investing.com South Africa
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock - Investing.com
CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants - Stock Titan
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares By Investing.com - Investing.com South Africa
Form 8K Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
TPST PE Ratio & Valuation, Is TPST Overvalued - Intellectia AI
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares - Investing.com
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):